Immuron’s Travelan anti-diarrhea product drives record revenue in North America

Immuron ASX IMC Travelan North America sales revenue 2019
Immuron’s revenue from Travelan sales exceeded $1 million for the first time in the United States.

Immuron (ASX: IMC) revealed its full year 2019 revenue in North America has grown more than 50% to reach $1.16 million – driven by its Travelan gastrointestinal and digestive prophylactic health supplement to prevent traveller’s diarrhea.

In the US, revenue from Travelan sales exceeded $1 million for the first time, with the product’s sales increasing more than 32% year-on-year to reach $1.02 million in FY2019.

“During the 2019 fiscal year, Immuron added to the ongoing successful efforts in Australia by working hard to increase awareness of Travelan among North American consumers, using podcasts and collaborations with travel bloggers to educate and inform the market regarding the virtues of our product,” Immuron chief executive officer Dr Gary Jacob said.

“The new 2020 fiscal year will see our efforts ramp-up even further in North America as we expand distribution channels and work to further consumer demand in that very important geographic area using pull-through marketing campaigns and other forms of advertising,” Dr Jacob added.

During May, Travelan sales in the US hit a new monthly record of $182,000.

On a global level, Immuron’s sales for FY2019 rose 29% on the previous year – tipping $2.6 million.

Australian sales contributed $1.44 million which was a 15% year-on-year increase.

During the March quarter of FY2019, Travelan was launched into the Canadian market and achieved more than $100,000 in sales in the June quarter.

Travelan study results

Travelan sales are underpinned by studies carried out under cooperative research and development agreements with the US Department of Defense.

In June, Immuron reported positive results when Travelan was trialled in 12 juvenile rhesus monkeys to treat shigellosis or dysentery.

Only two of the eight Travelan-treated monkeys showed any signs of dysentery, while the entire placebo group displayed acute clinical signs of dysentery within 36 hours.

The trial revealed prophylactic administration of Travelan may help prevent Shigellosis or dysentery, which can cause up to 165 million cases of disease worldwide and results in 600,000 deaths a year – primarily in South Asia and sub-Saharan African regions.

This morning’s news spurred Immuron’s share price up more than 26% to $0.145.

Lorna has more than 10 years' experience as a finance journalist and editor. She has written for numerous industry publications reporting on various sectors, including: resources, energy, construction, biotech, pharma, science and technology, agriculture, and chemicals. Specialising in resources, Lorna has also covered a myriad of small and large cap ASX and dual-listed stocks.